Nature of the Business (Details) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended
	Mar. 12, 2024 USD ($) $ / shares shares	Jul. 18, 2023 shares	Jul. 31, 2023 USD ($) $ / shares shares	Nov. 30, 2022 Item	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($) shares	Dec. 31, 2024 USD ($)
Nature of the Business
Net proceeds from IPO	$ 450,000		$ 315,400
Accumulated deficit					$ (361,255)		$ (305,916)
Net Income (Loss)					(55,339)	$ (32,094)
Negative cash flows from operations					48,477	31,636
Cash and cash equivalents					106,916	$ 485,457
Marketable securities					406,413		378,864
Long-term marketable securities					$ 168,106		$ 210,416
IPO
Nature of the Business
Shares issued | shares	7,790,321	20,297,500	20,297,500
Share price | $ / shares	$ 62		$ 17
Overallotment option
Nature of the Business
Shares issued | shares	1,016,128		2,647,500			7,790,321
Option Agreement | Related party | Paragon Therapeutics, Inc
Nature of the Business
Number of selected targets initially included under the agreement | Item				2